# 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

> **NCT00186589** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Blood and Marrow Transplant (BMT)

## Interventions

- **DRUG:** 90Y Ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00186589
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00186589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00186589, "90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00186589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*